Navigation Links
Ardea Biosciences Appoints John W. Beck Chief Financial Officer, Announces Clinical Development Progress and Reports First Quarter 2008 Financial Results
Date:5/9/2008

nactive status) certified public accountant in the state of California and is a member of the American Institute of Certified Public Accountants and the Association of Bioscience Financial Officers.

Recent Accomplishments

In the first quarter of 2008, we continued to progress our development pipeline in all three therapeutic areas of focus, including:

-- Announced positive preliminary results for RDEA806, our lead non-

nucleoside reverse transcriptase inhibitor (NNRTI), in a Phase 2a

monotherapy study in patients with human-immunodeficiency virus (HIV),

demonstrating an up to 2.0 log placebo-adjusted reduction in plasma

viral load after seven days of treatment;

-- Completed a first-in-human micro-dosing study of our second generation

NNRTI, RDEA427, and selected it as a development candidate;

-- Completed a first-in-human micro-dosing study of our second generation

MEK inhibitor, RDEA436, and selected it as a development candidate;

-- Presented preclinical data demonstrating potent activity and favorable

resistance profiles for our next generation NNRTI family of compounds

against HIV at the 15th Annual Conference on Retroviruses and

Opportunistic Infections (CROI) and the 21st International Conference

on Antiviral Research (ICAR);

-- Presented preclinical data demonstrating the potent activity and

favorable pharmacokinetic profile of our mitogen-activated ERK kinase

(MEK) inhibitor family of compounds in the treatment of cancer,

preliminary Phase 1 data demonstrating the potential for once-daily

oral dosing of RDEA119, our lead MEK inhibitor, and first-in-human

micro-dose data for RDEA436, at the American Association for Cancer

Research (AACR);

-- Established two scientific advisory boards to guide the HIV and

inflammation programs; and

-- Relocated ou
'/>"/>

SOURCE Ardea Biosciences, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related medicine technology :

1. Ardea Biosciences, Inc. Announces Completion of Phase 1 Clinical Trials of Novel Investigational HIV Drug RDEA806
2. Ardea Biosciences, Inc. Presents Results of Phase 1 Studies of RDEA806, a Novel NNRTI for HIV, at 47th ICAAC
3. Ardea Biosciences Lead MEK Inhibitor, RDEA119, to Enter Human Clinical Trials in Advanced Cancer Patients
4. Ardea Biosciences, Inc. Announces New Clinical Development Program Directed Toward the Treatment of Gout
5. Ardea Biosciences Presents Preclinical Data Demonstrating Favorable Resistance Profiles for Non-Nucleoside Reverse Transcriptase Inhibitors for the Treatment of Human Immunodeficiency Virus
6. Ardea Biosciences Reports Positive Phase 2a Results for Lead HIV Candidate, RDEA806, Demonstrating up to 2.0 Log Reduction in Plasma Viral Load
7. Ardea Biosciences Presents Data Demonstrating Favorable Pharmacokinetics and Efficacy for Mitogen-Activated ERK Kinase (MEK) Inhibitors
8. ImmuneRegen BioSciences Reports Material Transfer Agreement with VaxGen, Inc.
9. ImmuneRegen BioSciences, Inc. Demonstrates Radilex(TM) Increases Disease-Fighting White Blood Cells
10. Upstream Biosciences Acquires Innovative Platform Technology and Drug Candidates for Tropical Parasitic Diseases
11. Alacrity Biosciences Announces Positive Results from a Phase 2 Study of Its Dry Eye Treatment ALTY-0501
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/18/2014)... , Sept. 18, 2014 Research ... "China PTCA Balloon Market Investment Report, 2014-2016" ... as a indispensable medical device in percutaneous coronary intervention ... stent, but also as a device for pre-/post-stent dilatations. ... related to that of PCI. As national ...
(Date:9/18/2014)... , Sept. 18, 2014  Decision Resources Group ... the United States , 54 percent ... BRAF inhibitor Tafinlar for BRAF -mutation-positive unresectable ... have prescribed GlaxoSmithKline,s MEK inhibitor Mekinist. Among current ... (42 percent and 43 percent, respectively) expects to ...
(Date:9/18/2014)... , Sept. 18, 2014   Fruit Street ... secured an initial seed round of funding. ... was led by a series of individual investors, the ... whom participated in the initial round are; Houston ... Medical Center Urologist Stacy Childs, Rapha Family Medicine Practice ...
Breaking Medicine Technology:China PTCA Balloon Market Investment Report, 2014-2016 2China PTCA Balloon Market Investment Report, 2014-2016 3At One Year Post-Launch, Approximately One Half of Surveyed U.S. Medical Oncologists Have Prescribed Single-Agent Tafinlar and Mekinist to Their Malignant Melanoma Patients 2Fruit Street Health Secures First Round Of Seed Funding Led By Group Of Medical Industry And Technology Leaders 2Fruit Street Health Secures First Round Of Seed Funding Led By Group Of Medical Industry And Technology Leaders 3
... 21 /PRNewswire-FirstCall / -- SPX Corporation (NYSE: ... the Anhydro business, a Soeborg, Denmark -based global supplier of ...  The terms of the transaction were not disclosed. , ... Anhydro supplies a wide range ...
... Young Innovations, Inc. (Nasdaq: YDNT ) today announced that its ... per share, payable September 15, 2010 to all shareholders ... Directors also authorized the repurchase of up to 500,000 shares of ... July 31, 2011 , replaces the current authorization which is scheduled ...
Cached Medicine Technology:SPX Completes Acquisition of Anhydro 2SPX Completes Acquisition of Anhydro 3Young Innovations, Inc. Board of Directors Declares Quarterly Dividend and Authorizes Share Repurchase Program 2
(Date:9/18/2014)... 2014 (HealthDay News) -- Daily supplements of selenium or ... development of age-related cataracts among men, a new study ... or both could help prevent cataracts. To investigate this ... Harvard Medical School in Boston, and his colleagues examined ... vitamin E. The trial was initially designed to study ...
(Date:9/18/2014)... Lake City, UT (PRWEB) September 18, 2014 ... North America will be recognizing their shared fundraising impact ... on Thursday, Sept. 25. , The first-ever Dance Marathon ... more than $20 million projected to be raised by ... their community’s CMN Hospital. Donations generated through Dance Marathon ...
(Date:9/18/2014)... scientists have developed a new method to study Ebola ... The Wildlife Conservation Society (WCS)-led research, published today in ... the use of fecal samples from wild great apes ... the virus. This represents a new tool for performing ... way Ebola virus is studied and improve our understanding ...
(Date:9/18/2014)... Dangerous new pathogens such as the Ebola virus invoke ... such as the bubonic plague are still providing researchers ... infections. , In a study published online Sept. 18, ... Duke Medicine and Duke-NUS Graduate Medical School Singapore detail ... hitchhike on immune cells in the lymph nodes and ...
(Date:9/18/2014)... Technology Association of Georgia in collaboration ... TAG Social Savvy Awards this week at a special ... Center in Downtown Atlanta. The event celebrates Georgia’s best ... was honored with the 2014 TAG Social Savvy People’s ... innovators in 6 other award categories: , ...
Breaking Medicine News(10 mins):Health News:Vitamin E, Selenium Supplements Don't Seem to Prevent Cataracts 2Health News:250 Campuses Usher in School Year of Saving Kids’ Lives During First-Ever “Dance Marathon Day” on Sept. 25 2Health News:Research yields a game changer for improving understanding of Ebola and great apes 2Health News:Research yields a game changer for improving understanding of Ebola and great apes 3Health News:New insights on an ancient plague could improve treatments for infections 2Health News:Winners Honored at 2014 TAG Social Savvy Awards 2Health News:Winners Honored at 2014 TAG Social Savvy Awards 3
... A group of Northeast Ohio breast,cancer survivors continue to ... the disease by participating in the sport of Dragon ... canoeing, involves a team of 22,paddlers racing in 40-foot-long ... the team offers women living with breast cancer an,opportunity ...
... Increasing temperatures, carbon dioxide levels add to discomfort of ... Add increased suffering for people with ragweed allergies to ... new study suggests. , Recent research indicates that ... longer ragweed seasons and more concentrated pollen counts, says ...
... certain genotype more affected, study finds , , MONDAY, Aug. ... containing codeine may be unwittingly risking the health of ... indicates that a relatively rare genetic predisposition causes some ... than normal -- possibly harming the infant,s central nervous ...
... at menopause as well as a woman,s breastfeeding practices ... breast cancer. That was the conclusion of a new ... CANCER, a peer-reviewed journal of the American ... distinct and separate hormonal risk factors associated with different ...
... Bikes Belong and Humana, launches Freewheelin ... bike-sharing initiative ... Inaugural Ride, DENVER, Aug. 24 Bike-sharing officially,rolled into Denver ... date: Freewheelin. Leading 100 cyclists,through the streets of Denver, Mayor Hickenlooper ...
... Benefit Group, LLC announces iCan Insurance, LLC ("iCan Insurance", "iCan") ... Inc. , ... Boca Raton, FL ... iCan Insurance, LLC ("iCan Insurance", "iCan") is now offering major ...
Cached Medicine News:Health News:Dragon Dream Team Continues to Send Message of Hope a Year Later 2Health News:Climate Change Linked to Longer Pollen Seasons 2Health News:Taking Codeine While Breast-Feeding May Harm Infant 2Health News:Taking Codeine While Breast-Feeding May Harm Infant 3Health News:Breastfeeding, other factors may affect risk of breast cancer type 2Health News:Kicking Into High Gear: Nation's Largest Bike-Sharing Program Debuts at Democratic National Convention 2Health News:Kicking Into High Gear: Nation's Largest Bike-Sharing Program Debuts at Democratic National Convention 3Health News:Kicking Into High Gear: Nation's Largest Bike-Sharing Program Debuts at Democratic National Convention 4Health News:iCan Benefit Group, LLC Announces: Major Medical Division Now Offers Avalon Healthcare Products 2
Microwell-EIA for the detection of GAD Autoantibody....
The NPT7 blood gas analyzer measures pH/blood gases and oximetry on 90 L sample volume with a two-step sampling procedure. Clinical tests compare NPT7 accuracy to that of benchtop analyzers. 30 sampl...
... GEM Premier 3000 simplifies and ... addition to unique features such ... and comprehensive menu options, the ... Intelligent Quality Management (iQM), an ...
... IRMA TRUpoint sets the standard for ... chemistries right at your patient's side ... This powerful, self contained system can ... CCU to ICU, or wherever you ...
Medicine Products: